REFERENCES
[1] Abdel Raheem
A, Johnson M, Ralph D, et al. Collagenase clostridium histolyticum: a
novel medical treatment for Peyronie’s disease. Minerva Urol Nefrol.
2018;70:380–385.
[2] Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy
of collagenase Clostridium histolyticum in the treatment of Peyronie’s
disease by subgroup: results from two large, double-blind, randomized,
placebo-controlled, phase III studies. BJU International.
2015;116:650–656.
[3] Schwarzer U, Sommer F, Klotz T, et al. The prevalence of
Peyronie’s disease: results of a large survey. BJU Int.
2001;88:727–730.
[4] Capoccia E, Levine LA. Contemporary Review of Peyronie’s Disease
Treatment. Curr Urol Rep. 2018;19:51.
[5] Tsambarlis P, Levine LA. Nonsurgical management of Peyronie’s
disease. Nat Rev Urol. 2019;16:172–186.
[6] Talib RA, Ibrahim MA, Cangüven Ö. Nonsurgical treatment options
in Peyronie’s Disease: 2016 update. Turk J Urol. 2016;42:217–223.
[7] Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and
effectiveness of collagenase clostridium histolyticum in the treatment
of Peyronie’s disease using a new modified shortened protocol. BJU Int.
2017;120:717–723.
[8] Yan S, Yap T, Minhas S. Collagenase clostridium histolyticum
intralesional injections for the treatment of Peyronie’s disease: a
safety profile. Transl Androl Urol. 2017;6:123–126.
[9] Bazzi M, Jamil ML, Dabaja AA. Outcomes of Surgery in Peyronie’s
Disease Following Intralesional Collagenase Clostridium Histolyticum
Injections. Curr Urol Rep. 2019;20:42.
[10] Mehdinasab SA, Alemohammad SA. Methylprednisolone acetate
injection plus casting versus casting alone for the treatment of de
Quervain’s tenosynovitis. Arch Iran Med. 2010;13:270–274.
[11] Evaniew N, Belley-Côté EP, Fallah N, et al. Methylprednisolone
for the Treatment of Patients with Acute Spinal Cord Injuries: A
Systematic Review and Meta-Analysis. J Neurotrauma. 2016;33:468–481.
[12] Turunç T, Deveci S, Güvel S, et al. The assessment of turkish
validation with 5 question version of international index of erectile
function (IIEF-5). Turkish Journal of Urology. 2007;33:45–49.
[13] Hellstrom Wayne J.G., Feldman Robert, Rosen Raymond C., et al.
Bother and Distress Associated with Peyronie’s Disease: Validation of
the Peyronie’s Disease Questionnaire. Journal of Urology.
2013;190:627–634.
[14] Capece M, Cocci A, Russo G, et al. Collagenase clostridium
histolyticum for the treatment of Peyronie’s disease: a prospective
Italian multicentric study. Andrology. 2018;6:564–567.
[15] Cocci A, Cito G, Urzì D, et al. Sildenafil 25 mg ODT +
Collagenase Clostridium hystoliticum vs Collagenase Clostridium
hystoliticum Alone for the Management of Peyronie’s Disease: A
Matched-Pair Comparison Analysis. J Sex Med. 2018;15:1472–1477.
[16] Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie’s
Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A
Randomized, Open-Label Pilot Study. J Sex Med. 2017;14:1430–1437.
[17] Dam E-JPM ten, Driel MF van, Jong IJ de, et al. Glimpses into
the molecular pathogenesis of Peyronie’s disease. The Aging Male.
2019;0:1–9.
[18] Rose AFD, Mantica G, Bocca B, et al. Supporting the role of
penile trauma and micro-trauma in the etiology of Peyronie’s disease.
Prospective observational study using the electronic microscope to
examine two types of plaques. The Aging Male. 2019;0:1–6.
[19] Gunes M, Aslan R, Eryılmaz R, et al. Levels of serum trace
elements in patients with Peyronie. The Aging Male. 2018;0:1–4.
[20] Paulis G, Brancato T. Inflammatory mechanisms and oxidative
stress in Peyronie’s disease: therapeutic “rationale” and related
emerging treatment strategies. Inflamm Allergy Drug Targets.
2012;11:48–57.
[21] Taylor FL, Levine LA. Peyronie’s Disease. Urol Clin North Am.
2007;34:517–534, vi.
[22] Bodner H, Howard AH, Kaplan JH. Peyronie’s disease;
cortisone-hyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol
Assoc. 1953;20:32–35.
[23] Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet
injection of dexamethasone. J Urol. 1975;114:898–900.
[24] Serefoglu EC, Smith TM, Kaufman GJ, et al. Factors Associated
With Erectile Dysfunction and the Peyronie’s Disease Questionnaire in
Patients With Peyronie Disease. Urology. 2017;107:155–160.
[25] Coyne KS, Currie BM, Thompson CL, et al. The test-retest
reliability of the Peyronie’s disease questionnaire. J Sex Med.
2015;12:543–548.
Table 1. Characteristics of the patients.